Drug Trial Radar · NCT04672395
A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19
Last checked: Nov 19, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31,454
Actual
Start
Mar 24, 2021
Primary completion
Sep 15, 2022
Study completion Apr 23, 2023
Sponsor
- Lead sponsor
- Clover Biopharmaceuticals AUS PtyIndustry
- Sponsor type
- Industry
- Collaborators
- Coalition for Epidemic Preparedness Innovations; International Vaccine Institute
- First posted
- Dec 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike (S)-protein subunit vaccine (SCB-2019) for the prevention of SARS-CoV-2-mediated COVID-19 in Participants Aged 12 Years and Older.
Conditions
- COVID-19
Interventions
CpG 1018/Alum-adjuvanted SCB-2019 vaccineBiological
Group 1: Participants will receive 1 intramuscular (IM) injection of 30 microgram (ug) SCB-2019 with CpG1018/Alum adjuvant on Day 1 and on Day 22
Placebo; 0.9% salineBiological
Group 2: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 1 and on Day 22
SCB-2019 vaccineBiological
Participants will receive 1 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant
SCB-2019 vaccine for PlaceboBiological
Participants will receive 2 IM injection of 30 microgram (ug) SCB-2019 with CpG 1018/alum adjuvant, 21 days apart
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with a First Occurrence of COVID-19 of Any Severity Starting 14 Days after Second Dose of SCB-2019Time frame: Day 36 up to Day 389 (1 year after second dose)
- Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 8 (7 days after first dose) and up to Day 29 (7 days after second dose)
- Number of Participants with Unsolicited AEsTime frame: Up to Day 43 (21 days after each dose)
- Number of Participants with Serious Adverse Events (SAEs), or Medically Attended AEs (MAAEs), or AEs Leading to Early Termination, or Adverse Events of Special Interest (AESIs)Time frame: Up to Day 389 (1 year after second dose)
- Non-inferiority of the neutralizing titers after third dose compared to the neutralizing titers after second doseTime frame: 14 days after third dose
- Non-inferiority of the neutralising titers in adolescents versus young adults.Time frame: 14 days after second dose
Locations
31 sites in 5 countries. Site status is shown where the registry gives one.
Anima
Alken, Belgium
Hôspital Erasme
Brussels, Belgium
Private Practice RESPISOM Namur
Namur, Belgium
Instituto D'OR de Pesquisa e Ensino
Rio de Janeiro, Rio Do Janeiro, Brazil
Instituto Atena de Pesquisa Clinica
Natal, Rio Grande do Norte, Brazil
CPCLIN - Centro de Pesquisas Clínicas de Natal
Natal, Rio Grande do Norte, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital da Universidade Federal de Santa Maria CEP/UFSM
Santa Maria, Rio Grande do Sul, Brazil
Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede, Acacias
Acacías, Colombia
Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede Aguazul
Aguazul, Colombia
Clínica de la Costa Ltda
Barranquilla, Colombia
Fundación Hospital Universitario del Norte
Barranquilla, Colombia
Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede, Bogotá D.C.
Bogotá, Colombia
Policlinico Social del Norte
Bogotá, Colombia
Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S.
Cali, Colombia
IPS Médicos Internistas de Caldas SAS
Manizales, Colombia
Centro de Atención e investigación Médica S.A.S, CAIMED S.A.S - sede, Yopal
Yopal, Colombia
Asian Hospital and Medical Center
City of Muntinlupa, Philippines
St. Luke's Medical Center
City of Taguig, Philippines
Las Pinas Doctors Hospital
Las Piñas, Philippines
Tropical Disease Foundation
Makati, Philippines
Manila Doctors Hospital
Manila, Philippines
University of the Philippines Manila - Philippine General Hospital
Pasay, Philippines
UERM Memorial Medical Center
Quezon City, Philippines
University of the East Ramon Magsaysay Memorial Medical Center
Quezon City, Philippines
FEU-NRMF Medical Center
Quezon City, Philippines
De La Salle Medical and Health Sciences Institute
Dasmariñas, Cavite, Philippines
Wits Clinical Research
Johannesburg, Gauteng, South Africa
DJW Research
Krugersdorp, Gauteng, South Africa
Soweto Clinical Trials Centre
Soweto, Gauteng, South Africa
Dr JM Engelbrecht Trial Site
Somerset West, Western Cape, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.